{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:35:42Z","timestamp":1790033742815,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Italian Ministry of Health \u2018Fondi Ricerca Corrente \u2013 Linea 2"},{"name":"Istituto di Ricovero e Cura a Carattere Scientifico"},{"DOI":"10.13039\/501100014835","name":"IRCCS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014835","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ivermectin is a key anthelmintic for the control of neglected tropical diseases. The main indications for population-level control with ivermectin through mass drug administration are onchocerciasis and lymphatic filariasis; however, there is interest in using higher, fixed-dose regimens for the control of scabies, soil-transmitted helminths and malaria. Safety data for these higher-dose regimens are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review and meta-analysis on the safety and doses of ivermectin was conducted. Eligible studies reported patient-level data and, for the meta-analysis, clinical trials reporting data on doses \u2265200 and \u2265400\u2009\u03bcg\/kg were included. Incidence ratios were used to compare adverse events by severity and organ system affected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The systematic search identified six studies for inclusion, revealing no differences in the number of individuals experiencing adverse events. A descriptive analysis of these clinical trials for a variety of indications showed no difference in the severity of the adverse events between standard (up to 400\u2009\u03bcg\/kg) and higher doses of ivermectin. Organ system involvement only showed an increase in ocular events in the higher-dose group in one trial for the treatment of onchocerciasis, all of them transient and mild to moderate in intensity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses. Ocular adverse events, despite being transient, are of concern in onchocerciasis patients. These data can inform programme managers and guide operational research activities as new approaches for the use of ivermectin are evaluated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz524","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T15:30:09Z","timestamp":1575300609000},"page":"827-834","source":"Crossref","is-referenced-by-count":119,"title":["Safety of high-dose ivermectin: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7727-1587","authenticated-orcid":false,"given":"Miriam","family":"Navarro","sequence":"first","affiliation":[{"name":"Department of Public Health, Science History and Gynecology, Universidad Miguel Hern\u00e1ndez de Elche, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Camprub\u00ed","sequence":"first","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal) Hospital Cl\u00ednic - Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Requena-M\u00e9ndez","sequence":"first","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal) Hospital Cl\u00ednic - Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0108-6822","authenticated-orcid":false,"given":"Dora","family":"Buonfrate","sequence":"first","affiliation":[{"name":"Department of Infectious \u2013 Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giorli","sequence":"first","affiliation":[{"name":"Department of Infectious \u2013 Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kamgno","sequence":"first","affiliation":[{"name":"Centre de Recherche sur les Filarioses et autres Maladies tropicales, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Gardon","sequence":"first","affiliation":[{"name":"Institut de Recherche pour le D\u00e9veloppement, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boussinesq","sequence":"first","affiliation":[{"name":"Institut de Recherche pour le D\u00e9veloppement, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal) Hospital Cl\u00ednic - Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Krolewiecki","sequence":"first","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal) Hospital Cl\u00ednic - Universitat de Barcelona, Barcelona, Spain"},{"name":"Instituto de Investigaciones de Enfermedades Tropicales Universidad Nacional de Salta\/CONICET, Or\u00e1n, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"2020031310475227100_dkz524-B1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.trstmh.2011.08.013","article-title":"Preventive chemotherapy in human helminthiasis: theoretical and operational aspects","volume":"105","author":"Gabrielli","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/clpt.2009.16","article-title":"Mass drug administration and integrated control for the world\u2019s high-prevalence neglected tropical diseases","volume":"85","author":"Hotez","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2020031310475227100_dkz524-B3","year":"2006"},{"key":"2020031310475227100_dkz524-B4","first-page":"589","article-title":"Summary of global update on preventive chemotherapy implementation in 2016: crossing the billion","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"2020031310475227100_dkz524-B5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-3156.2008.02049.x","article-title":"Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis","volume":"13","author":"Thylefors","year":"2008","journal-title":"Trop Med Int Health"},{"key":"2020031310475227100_dkz524-B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Ivermectin, \u2018wonder drug\u2019 from Japan: the human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2020031310475227100_dkz524-B7","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1500987","article-title":"Mass drug administration for scabies control in a population with endemic disease","volume":"373","author":"Romani","year":"2015","journal-title":"N Engl J Med"},{"key":"2020031310475227100_dkz524-B8","doi-asserted-by":"crossref","first-page":"153.","DOI":"10.1186\/1475-2875-12-153","article-title":"Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination","volume":"12","author":"Chaccour","year":"2013","journal-title":"Malar J"},{"key":"2020031310475227100_dkz524-B9","first-page":"96","article-title":"Efficacy of anthelminthic drugs and drug combinations against soil-transmitted helminths: a systematic review and network meta-analysis","volume":"68","author":"Clarke","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020031310475227100_dkz524-B10","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMp1900400","article-title":"Collateral benefits of preventive chemotherapy - expanding the war on neglected tropical diseases","volume":"380","author":"Hotez","year":"2019","journal-title":"N Engl J Med"},{"key":"2020031310475227100_dkz524-B11","doi-asserted-by":"crossref","first-page":"e0006003.","DOI":"10.1371\/journal.pntd.0006003","article-title":"Albendazole and ivermectin for the control of soil-transmitted helminths in an area with high prevalence of Strongyloides stercoralis and hookworm in northwestern Argentina: a community-based pragmatic study","volume":"11","author":"Echazu","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2020031310475227100_dkz524-B12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.apar.2015.02.005","article-title":"Strongyloidiasis with emphasis on human infections and its different clinical forms","volume":"88","author":"Toledo","year":"2015","journal-title":"Adv Parasitol"},{"key":"2020031310475227100_dkz524-B13","doi-asserted-by":"crossref","first-page":"e0005163.","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa","volume":"11","author":"Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2020031310475227100_dkz524-B14","year":"2017"},{"key":"2020031310475227100_dkz524-B15","doi-asserted-by":"crossref","first-page":"S4.","DOI":"10.1186\/1475-2883-2-S1-S4","article-title":"Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon","volume":"2 Suppl 1","author":"Boussinesq","year":"2003","journal-title":"Filaria J"},{"key":"2020031310475227100_dkz524-B16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"Gardon","year":"1997","journal-title":"Lancet"},{"key":"2020031310475227100_dkz524-B17","doi-asserted-by":"crossref","first-page":"168.","DOI":"10.1186\/s12936-017-1830-z","article-title":"Upon entering an age of global ivermectin-based integrated mass drug administration for neglected tropical diseases and malaria","volume":"16","author":"Richards","year":"2017","journal-title":"Malar J"},{"key":"2020031310475227100_dkz524-B18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.pt.2005.08.014","article-title":"Ivermectin 20 years on: maturation of a wonder drug","volume":"21","author":"Geary","year":"2005","journal-title":"Trends Parasitol"},{"key":"2020031310475227100_dkz524-B19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1473-3099(05)70192-4","article-title":"Mass chemotherapy options to control lymphatic filariasis: a systematic review","volume":"5","author":"Tisch","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"2020031310475227100_dkz524-B20","doi-asserted-by":"crossref","first-page":"162.","DOI":"10.1186\/s12936-017-1803-2","article-title":"Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways","volume":"16","author":"Chaccour","year":"2017","journal-title":"Malar J"},{"key":"2020031310475227100_dkz524-B21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(18)30163-4","article-title":"Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Smit","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020031310475227100_dkz524-B22","doi-asserted-by":"crossref","first-page":"e0006020.","DOI":"10.1371\/journal.pntd.0006020","article-title":"Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers","volume":"12","author":"Mu\u00f1oz","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2020031310475227100_dkz524-B23","year":"2009"},{"key":"2020031310475227100_dkz524-B24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1086\/657063","article-title":"Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels","volume":"51","author":"Dembele","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020031310475227100_dkz524-B25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4269\/ajtmh.1993.49.804","article-title":"Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea","volume":"49","author":"Kazura","year":"1993","journal-title":"Am J Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.trstmh.2003.10.018","article-title":"Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly","volume":"98","author":"Kamgno","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciy246","article-title":"Efficacy and safety of ivermectin against Trichuris trichiura in preschool-aged and school-aged children: a randomized controlled dose-finding trial","volume":"67","author":"Wimmersberger","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020031310475227100_dkz524-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpara.2009.11.001","article-title":"Unresolved issues in anthelmintic pharmacology for helminthiases of humans","volume":"40","author":"Geary","year":"2010","journal-title":"Int J Parasitol"},{"key":"2020031310475227100_dkz524-B29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.trstmh.2004.04.003","article-title":"A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results","volume":"99","author":"Fobi","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B30","doi-asserted-by":"crossref","first-page":"e0006454.","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: observations from a review of the literature","volume":"12","author":"Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2020031310475227100_dkz524-B31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4269\/ajtmh.1995.52.94","article-title":"Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions","volume":"52","author":"Njoo","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0035-9203(99)90305-X","article-title":"The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients","volume":"93","author":"Awadzi","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B33","first-page":"707","article-title":"Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials","volume":"67","author":"De Sole","year":"1989","journal-title":"Bull World Health Organ"},{"key":"2020031310475227100_dkz524-B34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.trstmh.2006.12.004","article-title":"Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis","volume":"101","author":"Ramaiah","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002401382731","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"Guzzo","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"2020031310475227100_dkz524-B36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pt.2014.07.001","article-title":"The advent of ivermectin: people, partnerships, and principles","volume":"30","author":"Crump","year":"2014","journal-title":"Trends Parasitol"},{"key":"2020031310475227100_dkz524-B37","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jac\/dkz083","article-title":"Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2\u201312 years","volume":"74","author":"Schulz","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020031310475227100_dkz524-B38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin\u2014do they occur beyond the indication of onchocerciasis?","volume":"98","author":"Chandler","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"2020031310475227100_dkz524-B39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpt.1219","article-title":"Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL)","volume":"105","author":"Smit","year":"2019","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/4\/827\/32903569\/dkz524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/4\/827\/32903569\/dkz524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T05:23:25Z","timestamp":1590125005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/4\/827\/5710696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,1,20]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz524","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,1,20]]}}}